CVS Health Chooses Novo Nordisk's Wegovy as Preferred Weight-Loss Drug

Published 55 minutes agoCVS

CVS Health Chooses Novo Nordisk's Wegovy as Preferred Weight-Loss Drug

CVS Health has announced a major shake-up in its drug formulary by designating Novo Nordisk's Wegovy as its preferred weight-loss drug, effective July 1. In this strategic decision, CVS will also exclude Eli Lilly's Zepbound from its standard formulary, according to a report from AP News. The move puts Wegovy and Saxenda, both from Novo Nordisk, in prime positions within the CVS system, potentially impacting patient access to alternative medications.

This formulary shift is accompanied by a pricing strategy from CVS Health that offers Wegovy at a discounted rate of around $500 per month for uninsured customers. This competitive pricing could sway consumer choice in the growing market for GLP-1 weight-loss drugs. According to Reuters, this development arrives amid intensified rivalry between Wegovy and Zepbound, both actively competing for market share in this sector.

Despite reporting strong first-quarter financial performance, Eli Lilly experienced a downturn in its stock price following the news of CVS's exclusion of Zepbound from prescription coverage. However, CVS Health appears to be optimistic about its financial future, having raised its full-year 2025 profit forecast—a positive signal as it navigates recovery from earlier challenges.

Share this article

Twitter Facebook LinkedIn

Recent Articles

Universal Display Announces $100 Million Stock Buyback Program

Universal Display Announces $100 Million Stock Buyback Program

25 minutes agoOLED

Universal Display Corporation, listed on Nasdaq as OLED, has unveiled plans for a $100 million stock buyback program. This strategic move, authorized by the company's Board of Directors, is designed to boost shareholder value while demonstrating confidence in its financial health and future outlook. The buyback will be funded from the company's existing cash reserves and allows for flexibility in execution, as it can be carried out through various means such as open market or privately negotiated transactions. Notably, there is no set expiration date for the program, allowing it to be adjusted according to market conditions and other relevant factors. This announcement comes on the heels of several shareholder-focused initiatives. Recently, Universal Display increased its quarterly dividend by 12.5% to $0.45 per share, underscoring its commitment to delivering value to investors. Stocktitan.net reported on these developments, highlighting the company's continued efforts to reward shareholders amidst strong financial performance. As of May 1, 2025, Universal Display's stock is trading at $141.09, marking a 12.29% rise from the previous close. The stock saw an opening price of $130.01 and experienced a trading range between an intraday low of $126.66 and a high of $145.88, with a volume of 2,793,894 shares. This positive stock movement aligns with the company's efforts to enhance shareholder returns through its aggressive financial strategies.

Wells Fargo Adjusts Ashland Inc. Price Target Amid Growth Concerns

Wells Fargo Adjusts Ashland Inc. Price Target Amid Growth Concerns

40 minutes agoASH

Wells Fargo has taken a cautious stance on Ashland Inc. (NYSE: ASH) by lowering its price target from $95.00 to $90.00 while retaining an "Overweight" rating. This decision comes amid concerns over the company's ability to maintain robust growth, especially as tariff challenges loom on the horizon. The bank's downgrade is underpinned by several factors, namely uncertainties in Ashland's growth trajectory. Issues such as customer de-stocking and a lack of clarity in underlying customer demand have raised red flags. Additionally, the possibility of new tariffs being introduced in 2025 is expected to impact broader economic growth, which could, in turn, affect Ashland's performance. These factors collectively influenced Wells Fargo's price target adjustment. Despite these adjustments, Wells Fargo still sees Ashland's stock as fairly valued, keeping an Equal Weight rating, indicating a neutral outlook. Investors are keeping a close eye on how these growth and tariff-related challenges will play out and potentially impact Ashland's financial health moving forward, according to reports from sources like TipRanks.

CVS Health Chooses Novo Nordisk's Wegovy as Preferred Weight-Loss Drug

CVS Health Chooses Novo Nordisk's Wegovy as Preferred Weight-Loss Drug

55 minutes agoCVS

CVS Health has announced a major shake-up in its drug formulary by designating Novo Nordisk's Wegovy as its preferred weight-loss drug, effective July 1. In this strategic decision, CVS will also exclude Eli Lilly's Zepbound from its standard formulary, according to a report from AP News. The move puts Wegovy and Saxenda, both from Novo Nordisk, in prime positions within the CVS system, potentially impacting patient access to alternative medications. This formulary shift is accompanied by a pricing strategy from CVS Health that offers Wegovy at a discounted rate of around $500 per month for uninsured customers. This competitive pricing could sway consumer choice in the growing market for GLP-1 weight-loss drugs. According to Reuters, this development arrives amid intensified rivalry between Wegovy and Zepbound, both actively competing for market share in this sector. Despite reporting strong first-quarter financial performance, Eli Lilly experienced a downturn in its stock price following the news of CVS's exclusion of Zepbound from prescription coverage. However, CVS Health appears to be optimistic about its financial future, having raised its full-year 2025 profit forecast—a positive signal as it navigates recovery from earlier challenges.

Tandem Diabetes Care Stock Soars on Earnings Beat

Tandem Diabetes Care Stock Soars on Earnings Beat

1 hours agoTNDM

Tandem Diabetes Care Inc. experienced a significant boost in its stock value following the release of its first-quarter 2024 financial results. The company reported an adjusted loss per share of $0.65, which came in better than the expected loss of $0.76. This positive performance was highlighted by a 22% increase in the company's stock price, showcasing strong investor confidence as noted by Fool.com. The company's revenue reached $192.8 million during the quarter, exceeding the consensus estimate of $174 million. This marks a 12% growth from the previous year. Notably, Tandem's international sales surged by 63%, contributing significantly to its overall revenue increase, according to Investing.com. Tandem has been focused on expanding its product line, which includes the recent launch of the Tandem Mobi insulin pump integrated with the Dexcom G6 CGM sensor, as well as the t:slim X2 with Abbott FreeStyle Libre 2 Plus CGM sensor. These strategic developments underscore the company's firm foothold in the market and its capability to foster growth through innovation and international expansion.